Harmony Biosciences Holdings, I (HRMY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.50
- Estimate
- $1.15
- Surprise
- +30.6%
- Revenue (period 2026-06-30)
- $261.3M
- Score at report (before → after)
- 7.0 → 7.0/10
Revenue source: xbrl.
How the report landed
Harmony Biosciences Holdings, I (HRMY) beat the $1.15 estimate with adjusted EPS of $1.50 — a large 30.6% upside surprise. TrendMatrix's engine moved from Hold (7.0/10) to Buy (Wait) at 7.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates HRMY Buy (Wait) at 6.4/10.
1 of the last 4 quarters beat the estimate; this quarter's +30.6% surprise compares with a -14.3% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- Positive news sentiment (+0.67)
- High-quality business
What argues against it
- Concentration risk — Product: WAKIX
- Concentration risk — Supplier: sole-source suppliers and manufacturers
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $33.76
- Entry target
- $32.08
- Price target
- $41.83
- Stop
- $29.83
- Upside to target
- +23.9%
- Reward-to-risk
- 2.5:1
The stock trades at 11.2× trailing but 5.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-14 — shown for context, not personalized investment advice.
HRMY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.98B
- P/E (fwd)
- 5.6
- P/E (ttm)
- 11.2
- 52-week range
- $25.90–$43.49
- Off 52-week high
- 22.4%
- RSI (14)
- 36
- Volume vs avg
- 0.69×
- Score today
- 6.4/10